September 28, 2022
Sumitomo Pharma has filed an appeal seeking to reverse the 2021 decision of the US Patent and Trademark Office (USPTO) that found the method of use patent related to its atypical antipsychotic agent Latuda (lurasidone) unpatentable, the company said on...read more